Product Images Rocuronium Bromide

View Photos of Packaging, Labels & Appearance

BOX LABEL - 0409 3189 01 ROCURONIUM BROMIDE Package Label (1)
SERIALIZED LABEL - 51662 1641 1
HOW SUPPLIED - How supplied 51662 1641 1
FIGURE 1 - figure 1 51662 1641 1
figure 2 - figure 2 51662 1641 1
figure 3 - figure 3 51662 1641 1
Structure - structure 51662 1641 1
Table 1 - table 1 51662 1641 1
Table 10 - table 10 51662 1641 1
Table 2 - table 2 51662 1641 1
Table 3 - table 3 51662 1641 1
TABLE 4 - table 4 51662 1641 1
TABLE 5 - table 5 51662 1641 1
TABLE 6 - table 6 51662 1641 1
table 7 - table 7 51662 1641 1
table 8 - table 8 51662 1641 1
Table 9 - table 9 51662 1641 1

Product Label Images

The following 17 images provide visual information about the product associated with Rocuronium Bromide NDC 51662-1641 by Hf Acquisition Co Llc, Dba Healthfirst, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

BOX LABEL - 0409 3189 01 ROCURONIUM BROMIDE Package Label (1)

This text seems to be a label for a medication called Rocuronium Bromide. It is specified as a paralyzing agent for intravenous use only. The label also provides details such as the NDC number (0409-7037-01) and that it is a 10mL multiple dose vial. Additionally, there is an expiration date mentioned but not clearly visible.*

SERIALIZED LABEL - 51662 1641 1

HOW SUPPLIED - How supplied 51662 1641 1

FIGURE 1 - figure 1 51662 1641 1

figure 2 - figure 2 51662 1641 1

figure 3 - figure 3 51662 1641 1

Structure - structure 51662 1641 1

Table 1 - table 1 51662 1641 1

This text appears to show a table with patient weight, drug delivery rate in mcg/kg/min, and infusion delivery rate in mL/h. Each row seems to correspond to a specific patient weight with different drug delivery rates and infusion rates indicated. The data in the table may be helpful for healthcare professionals in determining the appropriate drug and infusion rates based on patient weight.*

Table 10 - table 10 51662 1641 1

Table 2 - table 2 51662 1641 1

This text seems to contain a table showing the relationship between patient weight, drug delivery rate in mcg/kg/min, and infusion delivery rate in mL/hr. It outlines different weight ranges and the corresponding drug delivery rates per minute as well as the corresponding infusion delivery rates in milliliters per hour. This information can be useful for healthcare professionals to accurately administer medications based on a patient's weight.*

Table 3 - table 3 51662 1641 1

This appears to be a table showing drug delivery rates in mega/kg/min and mL/hz based on patient weight categories. The table provides a useful reference for calculating the appropriate drug delivery rate based on the weight of the patient. It can be used by healthcare professionals to ensure accurate medication dosages for different patient weights.*

TABLE 4 - table 4 51662 1641 1

This text appears to provide information about rocuronium bromide doses administered in mg/kg, the percentage of patients with excellent or good intubating conditions, and the time to completion of intubation in minutes. The table shows different dosage levels of rocuronium bromide and the corresponding outcomes in terms of intubating conditions and time required for intubation. This information could be useful for medical professionals and anesthesiologists in determining appropriate doses and monitoring patient responses during intubation procedures.*

TABLE 5 - table 5 51662 1641 1

TABLE 6 - table 6 51662 1641 1

table 7 - table 7 51662 1641 1

table 8 - table 8 51662 1641 1

This text provides information on pharmacokinetic parameters related to normal renal function, renal transplant patients, and hepatic dysfunction. It includes details such as clearance, volume of distribution, steady state, and elimination half-life.*

Table 9 - table 9 51662 1641 1

This text provides pharmacokinetic (PK) parameters for different age ranges of patients. The parameters include clearance (L/kg/hr), volume of distribution, and 3t steady-state elimination values. The age groups mentioned are <12 months, 1 to <3 years, and 3 to <8 years. The values for clearance, volume of distribution, and elimination are specified with their respective standard deviations in parentheses. These PK parameters are essential for understanding how medications behave in different age groups and can help in optimizing drug dosages for pediatric patients.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents